{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:57:57Z","timestamp":1789747077052,"version":"4.0.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant tumors associated with drug resistance present a significant challenge for clinicians and drug developers. Mutations and alterations within the tumor microenvironment frequently drive cancer cell invasion and metastasis. Despite identifying numerous molecular targets and lead compounds, achieving sustained efficacy remains challenging due to the rapid mutation rates and the emergence of resistance. Recently, Focal Adhesion Kinase (FAK), a non-receptor tyrosine kinase, has emerged as a promising target for inhibiting cancer progression, with several lead molecules advancing through clinical trials. FAK plays a critical role in cancer pathology by regulating cell adhesion, migration, proliferation, and survival. Its structure comprises three domains- the N-terminal FERM domain, kinase domain, and C-terminal focal adhesion targeting domain- contributing to its functional versatility. Ligands targeting the FERM and kinase domains can suppress cancer cell proliferation, invasion, and migration. The FERM domain, a member of the ezrin, radixin, and moesin family, is particularly noteworthy for its ligand-binding capabilities and potential to inhibit tumor growth. While FAK is a compelling anticancer target, challenges such as tissue-specific physiological variability and broad ligand specificity remain. This review provides a detailed analysis of FAK\u2019s role in cancer progression and explores emerging molecules targeting FAK as potential treatments for drug-resistant malignant tumors.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s11033-025-10296-7","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:17:21Z","timestamp":1740021441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors"],"prefix":"10.1007","volume":"52","author":[{"given":"Jaya","family":"Aakriti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megh Pravin","family":"Vithalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swastika","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaprasad","family":"Baby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakara R.","family":"Nagareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"10296_CR1","doi-asserted-by":"publisher","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai C-J, Jang H (2021) Anticancer drug resistance: an update and perspective. Drug Resist Updates 59:100796. https:\/\/doi.org\/10.1016\/j.drup.2021.100796","journal-title":"Drug Resist Updates"},{"key":"10296_CR2","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.3390\/ijms23137376","volume":"23","author":"A Dricu","year":"2022","unstructured":"Dricu A (2022) Oncogenic signalling of growth factor receptors in Cancer: mechanisms and Therapeutic opportunities. Int J Mol Sci 23:7376. https:\/\/doi.org\/10.3390\/ijms23137376","journal-title":"Int J Mol Sci"},{"key":"10296_CR3","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cells9102308","volume":"9","author":"JH Park","year":"2020","unstructured":"Park JH, Pyun WY, Park HW (2020) Cancer Metabolism: phenotype, signaling and therapeutic targets. Cells 9:2308. https:\/\/doi.org\/10.3390\/cells9102308","journal-title":"Cells"},{"key":"10296_CR4","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 221:107753. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753","journal-title":"Pharmacol Ther"},{"key":"10296_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14:598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792","journal-title":"Nat Rev Cancer"},{"key":"10296_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-642-27841-9_2228-2","volume-title":"Encyclopedia of Cancer","author":"J Haier","year":"2015","unstructured":"Haier J (2015) Focal adhesion kinase. In: Schwab M (ed) Encyclopedia of Cancer. Springer Berlin Heidelberg, Berlin, Heidelberg, pp 1\u20135. https:\/\/doi.org\/10.1007\/978-3-642-27841-9_2228-2."},{"key":"10296_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/biom10020179","volume":"10","author":"P Tapial Mart\u00ednez","year":"2020","unstructured":"Tapial Mart\u00ednez P, L\u00f3pez Navajas P, Lietha D (2020) FAK structure and regulation by Membrane Interactions and Force in focal adhesions. Biomolecules 10:179. https:\/\/doi.org\/10.3390\/biom10020179","journal-title":"Biomolecules"},{"key":"10296_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/s1357-2725(97)00008-3","volume":"29","author":"I Zachary","year":"1997","unstructured":"Zachary I (1997) Focal adhesion kinase. Int J Biochem Cell Biol 29:929\u2013934. https:\/\/doi.org\/10.1016\/s1357-2725(97)00008-3","journal-title":"Int J Biochem Cell Biol"},{"key":"10296_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1242\/jcs.00373","volume":"116","author":"JT Parsons","year":"2003","unstructured":"Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409\u20131416. https:\/\/doi.org\/10.1242\/jcs.00373","journal-title":"J Cell Sci"},{"key":"10296_CR10","doi-asserted-by":"publisher","first-page":"32442","DOI":"10.1021\/acsomega.2c03951","volume":"7","author":"M Shi","year":"2022","unstructured":"Shi M, Chen T, Wei S, Zhao C, Zhang X, Li X et al (2022) Molecular Docking, Molecular Dynamics Simulations, and Free Energy calculation insights into the binding mechanism between VS-4718 and focal adhesion kinase. ACS Omega 7:32442\u201332456. https:\/\/doi.org\/10.1021\/acsomega.2c03951","journal-title":"ACS Omega"},{"key":"10296_CR11","doi-asserted-by":"publisher","unstructured":"Zhang Z, Li J, Jiao S, Han G, Zhu J, Liu T Functional and clinical characteristics of focal adhesion kinases in cancer progression. Front Cell Dev Biol 2022;10. https:\/\/doi.org\/10.3389\/fcell.2022.1040311","DOI":"10.3389\/fcell.2022.1040311"},{"key":"10296_CR12","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/S0969-2126(02)00907-3","volume":"10","author":"J Nowakowski","year":"2002","unstructured":"Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP et al (2002) Structures of the Cancer-related Aurora-A, FAK, and EphA2 protein kinases from Nanovolume Crystallography. Structure 10:1659\u20131667. https:\/\/doi.org\/10.1016\/S0969-2126(02)00907-3","journal-title":"Structure"},{"key":"10296_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001Associateeditor:B.Teicher","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee BY, Timpson P, Horvath LG, Daly RJ (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146:132\u2013149. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.10.001Associateeditor:B.Teicher","journal-title":"Pharmacol Ther"},{"key":"10296_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13543776.2018.1414183","volume":"28","author":"P-C Lv","year":"2018","unstructured":"Lv P-C, Jiang A-Q, Zhang W-M, Zhu H-L (2018) FAK inhibitors in Cancer, a patent review. Expert Opin Ther Pat 28:139\u2013145. https:\/\/doi.org\/10.1080\/13543776.2018.1414183","journal-title":"Expert Opin Ther Pat"},{"key":"10296_CR15","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez Wusener AE, Gonz\u00e1lez \u00c1, Perez Collado ME, Maza MR, General IJ, Arregui CO (2021) Protein tyrosine phosphatase 1B targets focal adhesion kinase and paxillin in cell-matrix adhesions. J Cell Sci 134. https:\/\/doi.org\/10.1242\/jcs.258769","DOI":"10.1242\/jcs.258769"},{"key":"10296_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/690690","volume":"2015","author":"Y-L Tai","year":"2015","unstructured":"Tai Y-L, Chen L-C, Shen T-L (2015) Emerging roles of focal adhesion kinase in Cancer. Biomed Res Int 2015:1\u201313. https:\/\/doi.org\/10.1155\/2015\/690690","journal-title":"Biomed Res Int"},{"key":"10296_CR17","doi-asserted-by":"publisher","first-page":"77468","DOI":"10.18632\/oncotarget.12684","volume":"7","author":"Q Cao","year":"2016","unstructured":"Cao Q, Mao Z-D, Shi Y-J, Chen Y, Sun Y, Zhang Q et al (2016) MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK\/MAPK signaling pathway. Oncotarget 7:77468\u201377481. https:\/\/doi.org\/10.18632\/oncotarget.12684","journal-title":"Oncotarget"},{"key":"10296_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.mvr.2011.06.015","volume":"83","author":"SY Yuan","year":"2012","unstructured":"Yuan SY, Shen Q, Rigor RR, Wu MH (2012) Neutrophil transmigration, focal adhesion kinase and endothelial barrier function. Microvasc Res 83:82\u201388. https:\/\/doi.org\/10.1016\/j.mvr.2011.06.015","journal-title":"Microvasc Res"},{"key":"10296_CR19","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2337\/db11-1344","volume":"61","author":"EP Cai","year":"2012","unstructured":"Cai EP, Casimir M, Schroer SA, Luk CT, Shi SY, Choi D et al (2012) In vivo role of focal adhesion kinase in regulating pancreatic \u03b2-cell mass and function through insulin signaling, actin dynamics, and granule trafficking. Diabetes 61:1708\u20131718. https:\/\/doi.org\/10.2337\/db11-1344","journal-title":"Diabetes"},{"key":"10296_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/cancers10070221","volume":"10","author":"R Fontana","year":"2018","unstructured":"Fontana R, Vivo M (2018) Dynamics of p14ARF and focal adhesion kinase-mediated autophagy in cancer. Cancers (Basel) 10:13\u201315. https:\/\/doi.org\/10.3390\/cancers10070221","journal-title":"Cancers (Basel)"},{"key":"10296_CR21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/molecules23123110","volume":"23","author":"D-C Pham","year":"2018","unstructured":"Pham D-C, Chang Y-C, Lin S-R, Fuh Y-M, Tsai M-J, Weng C-F (2018) FAK and S6K1 inhibitor, Neferine, dually induces autophagy and apoptosis in human neuroblastoma cells. Molecules 23:3110. https:\/\/doi.org\/10.3390\/molecules23123110","journal-title":"Molecules"},{"key":"10296_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/19336918.2021.1892397","volume":"15","author":"AA Villanueva","year":"2021","unstructured":"Villanueva AA, Sanchez-Gomez P, Mu\u00f1oz-Palma E, Puvogel S, Casas BS, Arriagada C et al (2021) The netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-\u03b21 and focal adhesion kinase activation. Cell Adh Migr 15:58\u201373. https:\/\/doi.org\/10.1080\/19336918.2021.1892397","journal-title":"Cell Adh Migr"},{"key":"10296_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/08880018.2017.1360969","volume":"34","author":"P Kratimenos","year":"2017","unstructured":"Kratimenos P, Koutroulis I, Syriopoulou V, Michailidi C, Delivoria-Papadopoulos M, Klijanienko J et al (2017) FAK-Src-paxillin system expression and disease outcome in human neuroblastoma. Pediatr Hematol Oncol 34:221\u2013230. https:\/\/doi.org\/10.1080\/08880018.2017.1360969","journal-title":"Pediatr Hematol Oncol"},{"key":"10296_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/13543784.2024.2348068","volume":"33","author":"J Gao","year":"2024","unstructured":"Gao J, Cheng J, Xie W, Zhang P, Liu X, Wang Z et al (2024) Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study. Expert Opin Investig Drugs 33:639\u2013651. https:\/\/doi.org\/10.1080\/13543784.2024.2348068","journal-title":"Expert Opin Investig Drugs"},{"key":"10296_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13104-024-06953-y","volume":"17","author":"M Kamalabadi-Farahani","year":"2024","unstructured":"Kamalabadi-Farahani M, Kia V, Dylami S, Atashi A (2024) Integrins linked kinase and focal adhesion kinase as the key signaling mediators of vascular mimicry in metastatic breast tumor cells. BMC Res Notes 17:282. https:\/\/doi.org\/10.1186\/s13104-024-06953-y","journal-title":"BMC Res Notes"},{"key":"10296_CR26","doi-asserted-by":"publisher","unstructured":"Rigiracciolo DC, Santolla MF, Lappano R, Vivacqua A, Cirillo F, Galli GR et al Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. J Experimental Clin Cancer Res 2019;38. https:\/\/doi.org\/10.1186\/s13046-019-1056-8","DOI":"10.1186\/s13046-019-1056-8"},{"key":"10296_CR27","doi-asserted-by":"publisher","first-page":"116461","DOI":"10.1016\/j.bcp.2024.116461","volume":"229","author":"Z Feng","year":"2024","unstructured":"Feng Z, Wei W, Wang S, Li X, Zhao L, Wan G et al (2024) A novel selective FAK inhibitor E2 inhibits ovarian cancer metastasis and growth by inducing cytotoxic autophagy. Biochem Pharmacol 229:116461. https:\/\/doi.org\/10.1016\/j.bcp.2024.116461","journal-title":"Biochem Pharmacol"},{"key":"10296_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12032-023-02092-9","volume":"40","author":"Q Pan","year":"2023","unstructured":"Pan Q, Wang Q, Zhao T, Zhao X, Liang Y, Shi M et al (2023) FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest. Med Oncol 40:215. https:\/\/doi.org\/10.1007\/s12032-023-02092-9","journal-title":"Med Oncol"},{"key":"10296_CR29","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1158\/0008-5472.CAN-07-2667","volume":"67","author":"J Halder","year":"2007","unstructured":"Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T et al (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67:10976\u201310983. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2667","journal-title":"Cancer Res"},{"key":"10296_CR30","doi-asserted-by":"publisher","DOI":"10.7727\/wimj.2015.045","author":"M Reboe","year":"2015","unstructured":"Reboe M, Rathinavelu A, Levy A, Sivanesan D (2015) Vitamin E and focal adhesion kinase inhibitor Y15 enhances the cytotoxic effects of cisplatin\u2009+\u2009paclitaxel in platinum resistant ovarian Cancer cells. West Indian Med J. https:\/\/doi.org\/10.7727\/wimj.2015.045","journal-title":"West Indian Med J"},{"key":"10296_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","volume":"12","author":"X Tan","year":"2023","unstructured":"Tan X, Yan Y, Song B, Zhu S, Mei Q, Wu K (2023) Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol 12:83. https:\/\/doi.org\/10.1186\/s40164-023-00446-7","journal-title":"Exp Hematol Oncol"},{"key":"10296_CR32","doi-asserted-by":"publisher","unstructured":"Siu MKY, Jiang Y-X, Wang J-J, Leung THY, Han CY, Tsang BK et al (2019) Hexokinase 2 regulates ovarian cancer cell migration, invasion and stemness via. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11060813. FAK\/ERK1\/2\/MMP9\/NANOG\/SOX9 signaling cascades","DOI":"10.3390\/cancers11060813"},{"key":"10296_CR33","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ijc.29522","volume":"137","author":"C B\u00e9raud","year":"2015","unstructured":"B\u00e9raud C, Dormoy V, Danilin S, Lindner V, B\u00e9thry A, Hochane M et al (2015) Targeting FAK scaffold functions inhibits human renal cell carcinoma growth. Int J Cancer 137:1549\u20131559. https:\/\/doi.org\/10.1002\/ijc.29522","journal-title":"Int J Cancer"},{"key":"10296_CR34","doi-asserted-by":"publisher","first-page":"113569","DOI":"10.1016\/j.ejmech.2021.113569","volume":"222","author":"M Mustafa","year":"2021","unstructured":"Mustafa M, Abd El-Hafeez AA, Abdelhamid D, Katkar GD, Mostafa YA, Ghosh P et al (2021) A first-in-class anticancer dual HDAC2\/FAK inhibitors bearing hydroxamates\/benzamides capped by pyridinyl-1,2,4-triazoles. Eur J Med Chem 222:113569. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113569","journal-title":"Eur J Med Chem"},{"key":"10296_CR35","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/ijc.26303","volume":"130","author":"L Bai","year":"2012","unstructured":"Bai L, Yang JC, Ok J, Mack PC, Kung H, Evans CP (2012) Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer 130:2693\u20132702. https:\/\/doi.org\/10.1002\/ijc.26303","journal-title":"Int J Cancer"},{"key":"10296_CR36","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.18632\/oncotarget.27165","volume":"10","author":"JM Aye","year":"2019","unstructured":"Aye JM, Stafman LL, Williams AP, Garner EF, Stewart JE, Anderson JC et al (2019) The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor. Oncotarget 10:5534\u20135548. https:\/\/doi.org\/10.18632\/oncotarget.27165","journal-title":"Oncotarget"},{"key":"10296_CR37","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3892\/ijo.2019.4726","volume":"54","author":"X Hong","year":"2019","unstructured":"Hong X, Yu J-J (2019) Silencing of lysyl oxidase-like 2 inhibits the migration, invasion and epithelial-to-mesenchymal transition of renal cell carcinoma cells through the Src\/FAK signaling pathway. Int J Oncol 54:1676\u20131690. https:\/\/doi.org\/10.3892\/ijo.2019.4726","journal-title":"Int J Oncol"},{"key":"10296_CR38","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.canlet.2008.05.042","volume":"270","author":"T Kaneda","year":"2008","unstructured":"Kaneda T, Sonoda Y, Ando K, Suzuki T, Sasaki Y, Oshio T et al (2008) Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett 270:354\u2013361. https:\/\/doi.org\/10.1016\/j.canlet.2008.05.042","journal-title":"Cancer Lett"},{"key":"10296_CR39","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.4161\/cc.21611","volume":"11","author":"DA Ucar","year":"2012","unstructured":"Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A et al (2012) Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle 11:3250\u20133259. https:\/\/doi.org\/10.4161\/cc.21611","journal-title":"Cell Cycle"},{"key":"10296_CR40","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.3390\/cancers15082280","volume":"15","author":"M Tarin","year":"2023","unstructured":"Tarin M, N\u00e9mati F, Decaudin D, Canbezdi C, Marande B, Silva L et al (2023) FAK inhibitor-based combinations with MEK or PKC inhibitors trigger synergistic Antitumor effects in Uveal Melanoma. Cancers (Basel) 15:2280. https:\/\/doi.org\/10.3390\/cancers15082280","journal-title":"Cancers (Basel)"},{"key":"10296_CR41","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.bbrc.2019.01.050","volume":"509","author":"K Jeong","year":"2019","unstructured":"Jeong K, Murphy JM, Rodriguez YAR, Kim J-S, Ahn E-YE, Lim S-TS (2019) FAK inhibition reduces metastasis of \u03b14 integrin-expressing melanoma to lymph nodes by targeting lymphatic VCAM-1 expression. Biochem Biophys Res Commun 509:1034\u20131040. https:\/\/doi.org\/10.1016\/j.bbrc.2019.01.050","journal-title":"Biochem Biophys Res Commun"},{"key":"10296_CR42","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/s44321-024-00138-7","volume":"16","author":"C Pozzato","year":"2024","unstructured":"Pozzato C, Outeiro-Pinho G, Gali\u00e8 M, Ramadori G, Konstantinidou G (2024) ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer. EMBO Mol Med 16:2402\u20132426. https:\/\/doi.org\/10.1038\/s44321-024-00138-7","journal-title":"EMBO Mol Med"},{"key":"10296_CR43","doi-asserted-by":"publisher","first-page":"116246","DOI":"10.1016\/j.bcp.2024.116246","volume":"224","author":"M Yang","year":"2024","unstructured":"Yang M, Xiang H, Luo G (2024) Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biochem Pharmacol 224:116246. https:\/\/doi.org\/10.1016\/j.bcp.2024.116246","journal-title":"Biochem Pharmacol"},{"key":"10296_CR44","doi-asserted-by":"publisher","unstructured":"Geijerman E, Terrana F, Peters GJ, Deng D, Diana P, Giovannetti E et al Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer. Expert Opin Investig Drugs 2024:1\u201316. https:\/\/doi.org\/10.1080\/13543784.2024.2417762","DOI":"10.1080\/13543784.2024.2417762"},{"key":"10296_CR45","doi-asserted-by":"publisher","unstructured":"Chuang H-H, Huang M-S, Zhen Y-Y, Chuang C-H, Lee Y-R, Hsiao M et al FAK executes Anti-senescence via regulating EZH2 Signaling in Non-small Cell Lung Cancer cells. Biomedicines 2022;10:1937. https:\/\/doi.org\/10.3390\/biomedicines10081937","DOI":"10.3390\/biomedicines10081937"},{"key":"10296_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bjc.2016.190","volume":"115","author":"H Zhang","year":"2016","unstructured":"Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA et al (2016) Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Br J Cancer 115:203\u2013211. https:\/\/doi.org\/10.1038\/bjc.2016.190","journal-title":"Br J Cancer"},{"key":"10296_CR47","doi-asserted-by":"publisher","unstructured":"Nana FA, Hoton D, Ambroise J, Lecocq M, Vanderputten M, Sibille Y et al (2019) Increased expression and activation of FAK in small-cell lung cancer compared to non-small-cell lung cancer. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11101526","DOI":"10.3390\/cancers11101526"},{"key":"10296_CR48","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.4161\/cc.8.15.9145","volume":"8","author":"SN Hochwald","year":"2009","unstructured":"Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA et al (2009) A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle 8:2435\u20132443. https:\/\/doi.org\/10.4161\/cc.8.15.9145","journal-title":"Cell Cycle"},{"key":"10296_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/15384047.2017.1416937","volume":"19","author":"R Kanteti","year":"2018","unstructured":"Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J et al (2018) Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 19:316\u2013327. https:\/\/doi.org\/10.1080\/15384047.2017.1416937","journal-title":"Cancer Biol Ther"},{"key":"10296_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00066-020-01666-0","volume":"197","author":"AA Mohamed","year":"2021","unstructured":"Mohamed AA, Thomsen A, Follo M, Zamboglou C, Bronsert P, Mostafa H et al (2021) FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro. Strahlenther Onkol 197:27\u201338. https:\/\/doi.org\/10.1007\/s00066-020-01666-0","journal-title":"Strahlenther Onkol"},{"key":"10296_CR51","doi-asserted-by":"publisher","unstructured":"Liu X, Baer JM, Stone ML, Knolhoff BL, Hogg GD, Turner MC et al (2024) Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Sci Transl Med 16. https:\/\/doi.org\/10.1126\/scitranslmed.ado2402","DOI":"10.1126\/scitranslmed.ado2402"},{"key":"10296_CR52","doi-asserted-by":"publisher","unstructured":"Jing Y, Liang W, Liu J, Zhang L, Wei J, Zhu Y et al (2019) Stress-induced phosphoprotein 1 promotes pancreatic cancer progression through activation of the FAK\/AKT\/MMP signaling axis. Pathol Res Pract 215. https:\/\/doi.org\/10.1016\/j.prp.2019.152564","DOI":"10.1016\/j.prp.2019.152564"},{"key":"10296_CR53","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1021\/acschembio.8b00250","volume":"13","author":"E Yen-Pon","year":"2018","unstructured":"Yen-Pon E, Li B, Acebr\u00f3n-Garcia-De-Eulate M, Tomkiewicz-Raulet C, Dawson J, Lietha D et al (2018) Structure-based design, synthesis, and characterization of the first irreversible inhibitor of focal adhesion kinase. ACS Chem Biol 13:2067\u20132073. https:\/\/doi.org\/10.1021\/acschembio.8b00250","journal-title":"ACS Chem Biol"},{"key":"10296_CR54","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1021\/acs.biochem.9b00541","volume":"58","author":"HS Loving","year":"2019","unstructured":"Loving HS, Underbakke ES (2019) Conformational dynamics of FERM-Mediated autoinhibition in Pyk2 tyrosine kinase. Biochemistry 58:3767\u20133776. https:\/\/doi.org\/10.1021\/acs.biochem.9b00541","journal-title":"Biochemistry"},{"key":"10296_CR55","doi-asserted-by":"publisher","unstructured":"Chuang H-H, Zhen Y-Y, Tsai Y-C, Chuang C-H, Hsiao M, Huang M-S et al (2022) FAK in Cancer: from mechanisms to therapeutic strategies. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23031726","DOI":"10.3390\/ijms23031726"},{"key":"10296_CR56","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.1074\/jbc.M606695200","volume":"282","author":"JK Slack-Davis","year":"2007","unstructured":"Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282:14845\u201314852. https:\/\/doi.org\/10.1074\/jbc.M606695200","journal-title":"J Biol Chem"},{"key":"10296_CR57","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","volume":"68","author":"WG Roberts","year":"2008","unstructured":"Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C et al (2008) Antitumor Activity and Pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935\u20131944. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5155","journal-title":"Cancer Res"},{"key":"10296_CR58","doi-asserted-by":"publisher","first-page":"762","DOI":"10.4161\/cbt.9.10.11434","volume":"9","author":"I Tanjoni","year":"2010","unstructured":"Tanjoni I, Walsh C, Uryu S, Tomar A, Nam J-O, Mielgo A et al (2010) PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther 9:762\u2013775","journal-title":"Cancer Biol Ther"},{"key":"10296_CR59","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1158\/1535-7163.MCT-06-0476","volume":"6","author":"T-J Liu","year":"2007","unstructured":"Liu T-J, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T et al (2007) Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6:1357\u20131367. https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0476","journal-title":"Mol Cancer Ther"},{"key":"10296_CR60","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/neuonc\/noy078","volume":"20","author":"NF Brown","year":"2018","unstructured":"Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L et al (2018) A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [ 11\u00a0C]GSK2256098. Neuro Oncol 20:1634\u20131642. https:\/\/doi.org\/10.1093\/neuonc\/noy078","journal-title":"Neuro Oncol"},{"key":"10296_CR61","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, Cleary JM, Razak ARA, Infante JR et al (2015) A phase i study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs 33:1100\u20131107. https:\/\/doi.org\/10.1007\/s10637-015-0282-y","journal-title":"Invest New Drugs"},{"key":"10296_CR62","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1517\/13543776.2014.948845","volume":"24","author":"E Shanthi","year":"2014","unstructured":"Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN (2014) Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat 24:1077\u20131100. https:\/\/doi.org\/10.1517\/13543776.2014.948845","journal-title":"Expert Opin Ther Pat"},{"key":"10296_CR63","doi-asserted-by":"publisher","unstructured":"Li H, Gao Y, Ren C (2021) Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K\/AKT\/mTOR signaling pathway in ovarian cancer. Discov Oncol 12(1):29. https:\/\/doi.org\/10.1007\/s12672-021-00425-6","DOI":"10.1007\/s12672-021-00425-6"},{"key":"10296_CR64","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/pros.23476","volume":"78","author":"H-M Lin","year":"2018","unstructured":"Lin H-M, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK et al (2018) Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate 78:308\u2013317. https:\/\/doi.org\/10.1002\/pros.23476","journal-title":"Prostate"},{"key":"10296_CR65","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1358\/dof.2014.039.011.2235834","volume":"39","author":"K Moore","year":"2014","unstructured":"Moore K, Walter A (2014) Defactinib hydrochloride. Dual FAK1\/PYK2 inhibitor, treatment of non-small cell lung cancer, treatment of malignant mesothelioma, treatment of ovarian cancer. Drugs Future 39:767. https:\/\/doi.org\/10.1358\/dof.2014.039.011.2235834","journal-title":"Drugs Future"},{"key":"10296_CR66","doi-asserted-by":"publisher","unstructured":"Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O\u2019Malley DM et al GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecologic Cancer 2024:ijgc-2024-005919. https:\/\/doi.org\/10.1136\/ijgc-2024-005919","DOI":"10.1136\/ijgc-2024-005919"},{"key":"10296_CR67","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","volume":"28","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam A, Lim K-H, McWilliams R, Suresh R, Lockhart AC, Brown A et al (2022) Defactinib, Pembrolizumab, and Gemcitabine in patients with Advanced Treatment Refractory Pancreatic Cancer: a phase I dose escalation and expansion study. Clin Cancer Res 28:5254\u20135262. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0308","journal-title":"Clin Cancer Res"},{"key":"10296_CR68","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/mc.23273","volume":"60","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhao D, Wang Y, Zhang W, Zhang J, Fan J et al (2021) Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K\/AKT axis and downstream molecular network. Mol Carcinog 60:113\u2013124. https:\/\/doi.org\/10.1002\/mc.23273","journal-title":"Mol Carcinog"},{"key":"10296_CR69","doi-asserted-by":"publisher","first-page":"112868","DOI":"10.1016\/j.yexcr.2021.112868","volume":"408","author":"J Liu","year":"2021","unstructured":"Liu J, Xue L, Xu X, Luo J, Zhang S (2021) FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer. Exp Cell Res 408:112868. https:\/\/doi.org\/10.1016\/j.yexcr.2021.112868","journal-title":"Exp Cell Res"},{"key":"10296_CR70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.vph.2018.06.017","volume":"110","author":"PA Lederer","year":"2018","unstructured":"Lederer PA, Zhou T, Chen W, Epshtein Y, Wang H, Mathew B et al (2018) Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase. Vascul Pharmacol 110:16\u201323. https:\/\/doi.org\/10.1016\/j.vph.2018.06.017","journal-title":"Vascul Pharmacol"},{"key":"10296_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1535-7163.mct-18-0328","volume":"18","author":"F Aboubakar Nana","year":"2019","unstructured":"Aboubakar Nana F, Lecocq M, Ladjemi MZ, Detry B, Dupasquier S, Feron O et al (2019) Therapeutic potential of focal adhesion kinase inhibition in small cell Lung Cancer. Mol Cancer Ther 18:17\u201327. https:\/\/doi.org\/10.1158\/1535-7163.mct-18-0328","journal-title":"Mol Cancer Ther"},{"key":"10296_CR72","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-17-0375","volume":"25","author":"S Wang","year":"2019","unstructured":"Wang S, Hwang EE, Guha R, O\u2019Neill AF, Melong N, Veinotte CJ et al (2019) High-throughput chemical screening identifies focal adhesion kinase and Aurora kinase B inhibition as a synergistic treatment combination in ewing sarcoma. Clin Cancer Res 25:4552\u20134566. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0375","journal-title":"Clin Cancer Res"},{"key":"10296_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-019-4389-7","volume":"12","author":"S Fukami","year":"2019","unstructured":"Fukami S, Tomioka D, Murakami Y, Honda T, Hatakeyama S (2019) Pharmacological profiling of a dual FAK\/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models. BMC Res Notes 12:1\u20137. https:\/\/doi.org\/10.1186\/s13104-019-4389-7","journal-title":"BMC Res Notes"},{"key":"10296_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11523-018-00617-1","volume":"14","author":"MJA de Jonge","year":"2019","unstructured":"de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ et al (2019) Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with Advanced or metastatic nonhematologic malignancies. Target Oncol 14:43\u201355. https:\/\/doi.org\/10.1007\/s11523-018-00617-1","journal-title":"Target Oncol"},{"key":"10296_CR75","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon H, Dehart JP, Murphy JM, Lim STS (2015) Understanding the roles of FAK in Cancer: inhibitors, genetic models, and New insights. J Histochem Cytochem 63:114\u2013128. https:\/\/doi.org\/10.1369\/0022155414561498","journal-title":"J Histochem Cytochem"},{"key":"10296_CR76","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/carcin\/bgs120","volume":"33","author":"VM Golubovskaya","year":"2012","unstructured":"Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G et al (2012) A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1 3,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonog. Carcinogenesis 33:1004\u20131013. https:\/\/doi.org\/10.1093\/carcin\/bgs120","journal-title":"Carcinogenesis"},{"key":"10296_CR77","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/1535-7163.MCT-12-0701","volume":"12","author":"VM Golubovskaya","year":"2013","unstructured":"Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J et al (2013) Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 12:162\u2013172. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0701","journal-title":"Mol Cancer Ther"},{"key":"10296_CR78","doi-asserted-by":"publisher","unstructured":"Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C et al (2013) Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer 13. https:\/\/doi.org\/10.1186\/1471-2407-13-342","DOI":"10.1186\/1471-2407-13-342"},{"key":"10296_CR79","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/1878-0261.12610","volume":"14","author":"K Steinestel","year":"2020","unstructured":"Steinestel K, Trautmann M, Jansen E-P, Dirksen U, Rehk\u00e4mper J, Mikesch J-H et al (2020) Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in ewing sarcoma. Mol Oncol 14:248\u2013260. https:\/\/doi.org\/10.1002\/1878-0261.12610","journal-title":"Mol Oncol"},{"key":"10296_CR80","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.2174\/1389557521666210226150740","volume":"21","author":"P Arora","year":"2021","unstructured":"Arora P, Singh M, Singh V, Bhatia S, Arora S (2021) PROTACs in treatment of Cancer: a review. Mini-Reviews Med Chem 21:2347\u20132360. https:\/\/doi.org\/10.2174\/1389557521666210226150740","journal-title":"Mini-Reviews Med Chem"},{"key":"10296_CR81","doi-asserted-by":"publisher","first-page":"100413","DOI":"10.1016\/j.xinn.2023.100413","volume":"4","author":"J Li","year":"2023","unstructured":"Li J, Chen X, Lu A, Liang C (2023) Targeted protein degradation in cancers: Orthodox PROTACs and beyond. Innov 4:100413. https:\/\/doi.org\/10.1016\/j.xinn.2023.100413","journal-title":"Innov"},{"key":"10296_CR82","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.3390\/ijms23126381","volume":"23","author":"A Spallarossa","year":"2022","unstructured":"Spallarossa A, Tasso B, Russo E, Villa C, Brullo C (2022) The development of FAK inhibitors: a five-year update. Int J Mol Sci 23:6381. https:\/\/doi.org\/10.3390\/ijms23126381","journal-title":"Int J Mol Sci"},{"key":"10296_CR83","doi-asserted-by":"publisher","first-page":"767","DOI":"10.5246\/jcps.2024.09.057","volume":"33","author":"R Wang","year":"2024","unstructured":"Wang R, Zhao X, Hou H, Chen K, Liu S, Ren R et al (2024) Cutting-edge FAK-targeting PROTACs: design, synthesis, and biological evaluation. J Chin Pharm Sci 33:767\u2013782. https:\/\/doi.org\/10.5246\/jcps.2024.09.057","journal-title":"J Chin Pharm Sci"},{"key":"10296_CR84","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","volume":"45","author":"M Xu","year":"2024","unstructured":"Xu M, Gu X, Li C, Pan L, Zhu Z, Fan M et al (2024) A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. Acta Pharmacol Sin 45:2174\u20132185. https:\/\/doi.org\/10.1038\/s41401-024-01312-w","journal-title":"Acta Pharmacol Sin"},{"key":"10296_CR85","doi-asserted-by":"publisher","unstructured":"Koide E, Mohardt ML, Doctor ZM, Yang A, Hao M, Donovan KA et al Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity. ChemBioChem 2023;24. https:\/\/doi.org\/10.1002\/cbic.202300141","DOI":"10.1002\/cbic.202300141"},{"key":"10296_CR86","doi-asserted-by":"publisher","first-page":"17019","DOI":"10.1021\/jacs.8b08008","volume":"140","author":"PM Cromm","year":"2018","unstructured":"Cromm PM, Samarasinghe KTG, Hines J, Crews CM (2018) Addressing kinase-independent functions of Fak via PROTAC-Mediated degradation. J Am Chem Soc 140:17019\u201317026. https:\/\/doi.org\/10.1021\/jacs.8b08008","journal-title":"J Am Chem Soc"},{"key":"10296_CR87","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1080\/14756366.2022.2100886","volume":"37","author":"Q Qin","year":"2022","unstructured":"Qin Q, Wang R, Fu Q, Zhang G, Wu T, Liu N et al (2022) Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs. J Enzyme Inhib Med Chem 37:2241\u20132255. https:\/\/doi.org\/10.1080\/14756366.2022.2100886","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10296_CR88","doi-asserted-by":"publisher","first-page":"117584","DOI":"10.1016\/j.biopha.2024.117584","volume":"180","author":"S-H Zhang","year":"2024","unstructured":"Zhang S-H, Zeng N, Xu J-Z, Liu C-Q, Xu M-Y, Sun J-X et al (2024) Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs. Biomed Pharmacother 180:117584. https:\/\/doi.org\/10.1016\/j.biopha.2024.117584","journal-title":"Biomed Pharmacother"},{"key":"10296_CR89","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2022040322","volume":"40","author":"R Thakur","year":"2023","unstructured":"Thakur R, Suri CR, Kaur IP, Rishi P (2023) Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future challenges. Crit Rev Ther Drug Carrier Syst 40:49\u2013100. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2022040322","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10296_CR90","doi-asserted-by":"publisher","unstructured":"Antoniades I, Kyriakou M, Charalambous A, Kalalidou K, Christodoulou A, Christoforou M et al FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis. Cell Communication Signal 2021;19. https:\/\/doi.org\/10.1186\/s12964-020-00671-1","DOI":"10.1186\/s12964-020-00671-1"},{"key":"10296_CR91","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1158\/0008-5472.CAN-05-1661","volume":"66","author":"CA Garces","year":"2006","unstructured":"Garces CA, Kurenova EV, Golubovskaya VM, Cance WG (2006) Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 66:1446\u20131454. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1661","journal-title":"Cancer Res"},{"key":"10296_CR92","first-page":"375","volume":"68","author":"MD Basson","year":"2017","unstructured":"Basson MD, Zeng B, Wang S (2017) The C-terminal region of the focal adhesion kinase F1 domain binds Akt1 and inhibits pressure-induced cell adhesion. J Physiol Pharmacol 68:375\u2013383","journal-title":"J Physiol Pharmacol"},{"key":"10296_CR93","doi-asserted-by":"publisher","unstructured":"Hu Z, Slayton WB Integrin VLA-5 and FAK are good targets to improve treatment response in the Philadelphia chromosome positive acute lymphoblastic leukemia. Front Oncol 2014;4 MAY. https:\/\/doi.org\/10.3389\/fonc.2014.00112","DOI":"10.3389\/fonc.2014.00112"},{"key":"10296_CR94","doi-asserted-by":"publisher","unstructured":"nsal \u00dc, Liu J, Sicinski KM, Kumar K (2022) Future perspectives on peptide therapeutics. Pept Peptidomimetic Therapeutics: Bench Bedside 699\u2013726. https:\/\/doi.org\/10.1016\/B978-0-12-820141-1.00003-0","DOI":"10.1016\/B978-0-12-820141-1.00003-0"},{"key":"10296_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0150567","volume":"11","author":"GA Howe","year":"2016","unstructured":"Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J et al (2016) Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer. PLoS ONE 11:1\u201320. https:\/\/doi.org\/10.1371\/journal.pone.0150567","journal-title":"PLoS ONE"},{"key":"10296_CR96","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41416-019-0452-3","volume":"120","author":"G Mak","year":"2019","unstructured":"Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N et al (2019) A phase ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer 120:975\u2013981. https:\/\/doi.org\/10.1038\/s41416-019-0452-3","journal-title":"Br J Cancer"},{"key":"10296_CR97","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1158\/1535-7163.MCT-16-0282","volume":"15","author":"D Wang","year":"2016","unstructured":"Wang D, Chen Y, Chen Z, Yan F, Dai X, Ying M et al (2016) CT-707, a novel FAK inhibitor, synergizes with Cabozantinib to suppress Hepatocellular Carcinoma by blocking Cabozantinib-Induced. FAK Activation 15:2916\u20132926. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0282","journal-title":"FAK Activation"},{"key":"10296_CR98","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1530\/ERC-13-0019","volume":"20","author":"G Lazaro","year":"2013","unstructured":"Lazaro G, Smith C, Goddard L, Jordan N, McClelland R, Barrett-Lee P et al (2013) Targeting focal adhesion kinase in ER+\/HER2\u2009+\u2009breast cancer improves trastuzumab response. Endocr Relat Cancer 20:691\u2013704. https:\/\/doi.org\/10.1530\/ERC-13-0019","journal-title":"Endocr Relat Cancer"},{"key":"10296_CR99","doi-asserted-by":"publisher","unstructured":"Zhao X, Sun W, Puszyk WM, Wallet S, Hochwald S, Robertson K et al Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma 2017. https:\/\/doi.org\/10.1177\/1010428317699120","DOI":"10.1177\/1010428317699120"},{"key":"10296_CR100","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10585-015-9752-z","volume":"32","author":"I Moen","year":"2015","unstructured":"Moen I, Gebre M, Alonso-Camino V, Chen D, Epstein D, McDonald DM (2015) Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis 32:799\u2013817. https:\/\/doi.org\/10.1007\/s10585-015-9752-z","journal-title":"Clin Exp Metastasis"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10296-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:35:45Z","timestamp":1766853345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10296"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10296-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish has been obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}